EN
TR
Gender differences in applicability of guidelines in clinical practice of heart failure patients
Abstract
Aim: Treatment methods decreasing mortality in heart failure (HF) are provided in detail by updated guidelines. We aimed to provide true data in our department about the applicability of guidelines into clinical practice on management of HF patients and their follow-up status.
Materials and Methods: We retrospectively assessed the clinical data of patients hospitalized with HF between 2009 and 2010 in our hospital. All the collected data were used to assess the applicability of guidelines and follow-up status for a 5-year time period. A retrospective assessment was preferred in order to reflect the real clinical practice.
Results: There were 496 patients hospitalized for HF between January 2009 and January 2010. New onset and chronic HF were diagnosed in 24.4% and 75.6% respectively. The most common scenario of acute HF was pulmonary oedema (77%). Ischemic heart disease was the predominant etiology (49.2%). The median age of patients was 65.62±14.48 and 67.7% of them were male. HF therapies increased from admission to discharge, but decreased during follow-up. Median length of stay was 11.26±9.26 days and in hospital mortality 9.5%. The most common complication was infection (18.2%). During follow-up, hospitalization rate was 88.2% and long-term mortality 44.5%.
Conclusion: Patients with HF are far away from the cardiovascular prevention targets. The evidence-based therapy recommended by the guidelines was not sufficiently provided. The high rehospitalization and in hospital mortality rate was linked to high rate of pneumonia
Keywords
References
- Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14; 37 (27): 2129-200.
- Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun; 13 (6): 368-78.
- Sciatti E, Dallapellegrina L, Metra M, Lombardi CM. New drugs for the treatment of chronic heart failure with a reduced ejection fraction: What the future may hold. J Cardiovasc Med (Hagerstown). 2019 Oct; 20 (10): 650-9.
- Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006 Nov; 27 (22): 2725-36.
- Adams Jr KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-16.
- Sato N, Kajimoto K, Asai K. Et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: Rationale, design, and preliminary data Am Heart J 2010; 159: 949-55.
- Anguita Sánchez M; Clinical Characteristics, Treatment and Short-Term Morbidity and Mortality of Patients With Heart Failure Followed in Heart Failure Clinics. Results of the BADAPIC Registry Rev Esp Cardiol 2004; 57 (12): 1159.
- Lale Tokgözoğlu, Ergün Barış Kaya, Çetin Erol, et al. EUROASPIRE III: a comparison between Turkey and EuropeTürk Kardiyol Dern Arş - Arch Turk Soc Cardiol 2010; 38 (3): 164-72.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Publication Date
September 13, 2021
Submission Date
February 6, 2021
Acceptance Date
February 15, 2021
Published in Issue
Year 1970 Volume: 60 Number: 3